New drug shows promise for rare ovarian cancer in early trial

NCT ID NCT05348356

Completed Disease control Sponsor: SpringWorks Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested the drug nirogacestat in 53 people with recurrent ovarian granulosa cell tumors, a rare type of ovarian cancer. The goal was to see if the drug could shrink tumors or slow the disease. Participants took nirogacestat orally, and researchers measured how many responded to treatment and how long they lived without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nirogacestat (a gamma secretase inhibitor oral tablet)

What this could lead to

If it works, this could offer a new treatment option for people with recurrent ovarian granulosa cell tumors, potentially shrinking tumors or delaying progression.

What could go wrong

This is a small phase 2 trial with only 53 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian granulosa cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER OVARIAN GRANULOSA CELL TUMOR OVARIAN GRANULOSA-STROMAL TUMOR

Contacts and locations

Show contact details

Locations

AdventHealth Orlando

Orlando, Florida, 32804, United States
Columbia University Medical Center

New York, New York, 10032, United States
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
David C. Pratt Cancer Center

St Louis, Missouri, 63141, United States
Froedtert and Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Greater Baltimore Medical Center

Baltimore, Maryland, 21204, United States
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Jagiellonian Innovation Centre Clinical Research Centre

Krakow, 30-348, Poland
Maria Sklodowska-Curie Bialystok Oncology Center

Bialystok, 15-027, Poland
Maria Sklodowska-Curie National Institute of Oncology-National Research Institute, Clinic of Oncological Gynecology

Warsaw, 02-781, Poland
Memorial Sloan Kettering Cancer Institute

New York, New York, 10065, United States
OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
Orlando Health Cancer Institute

Orlando, Florida, 32806, United States
UCLA-JCCC Dept. of OBGYN - Women's Health Clinical Research Unit

Los Angeles, California, 90095, United States
USC/Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
UW/Fred Hutch Cancer Center

Seattle, Washington, 98109, United States
University Teaching Hospital Poznan, Department of Oncological Gynaecology

Poznan, 60-569, Poland
University of New Mexico Comprehensive Cancer Center

Albuquerque, New Mexico, 87102, United States
Women's Cancer Care

Covington, Louisiana, 70433, United States
Women's Cancer Center at Kettering

Kettering, Ohio, 45429, United States